Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

被引：13

作者：

Griguolo, Gaia ^{[1
,2
]}

Dieci, Maria Vittoria ^{[1
,2
]}

Pare, Laia ^{[3
,4
]}

Miglietta, Federica ^{[1
,2
]}

Generali, Daniele Giulio ^{[5
]}

Frassoldati, Antonio ^{[6
]}

Cavanna, Luigi ^{[7
]}

Bisagni, Giancarlo ^{[8
]}

Piacentini, Federico ^{[9
]}

Tagliafico, Enrico ^{[10
]}

Cagossi, Katia ^{[11
]}

Ficarra, Guido ^{[12
]}

Prat, Aleix ^{[3
,4
]}

Conte, Pierfranco ^{[1
,2
]}

Guarneri, Valentina ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] Ist Oncol Veneto IOV IRCCS, Div Oncol 2, Padua, Italy

[3] Hosp Clin Barcelona, IDIBAPS, Div Oncol, Barcelona, Spain

[4] SOLTI Breast Canc Res Grp, Barcelona, Spain

[5] AO Ist Ospitalieri Cremona, Multidisciplinary Unit Breast Pathol, Cremona, Italy

[6] S Anna Univ Hosp, Dept Morphol Surg & Expt Med, Clin Oncol, Ferrara, Italy

[7] Piacenza Gen Hosp, Dept Hematol & Oncol, Oncol Unit, Piacenza, Italy

[8] Azienda Unita Sanit Locale IRCCS Reggio Emil, Dept Oncol & Adv Technol, Oncol Unit, Reggio Emilia, Italy

[9] Univ Hosp Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Modena, Italy

[10] Univ Modena & Reggio Emilia, Ctr Genome Res, Modena, Italy

[11] Ramazzini Hosp, Breast Unit, Carpi, Italy

[12] Azienda Osped Univ Policlin Modena, Dept Pathol, Modena, Italy

来源：

NPJ BREAST CANCER | 2021年 / 7卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT; THERAPY;

D O I：

10.1038/s41523-021-00223-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

引用

页数：5

共 50 条

[21] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
Linnea T. Olsson
Alina M. Hamilton
Sarah C. Van Alsten
Jennifer L. Lund
Til Stürmer
Hazel B. Nichols
Katherine E. Reeder-Hayes
Melissa A. Troester
Breast Cancer Research and Treatment, 2024, 204 : 107 - 116
[22] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Gilchrist, Jenny
SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
[23] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
Abdou, Yara
Ivory, Joannie
Deal, Allison
Wardell, Ally
Wheless, Amy
Dees, Claire
Carey, Lisa
CANCER RESEARCH, 2024, 84 (09)
[24] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Minetta C. Liu
Javier Cortés
Joyce O’Shaughnessy
Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
[25] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Burstein, Harold J.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
[26] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
Olsson, Linnea T.
Hamilton, Alina M.
Van Alsten, Sarah C.
Lund, Jennifer L.
Sturmer, Til
Nichols, Hazel B.
Reeder-Hayes, Katherine E.
Troester, Melissa A.
BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
[27] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Liu, Minetta C.
Cortes, Javier
O'Shaughnessy, Joyce
CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
[28] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Burstein, Harold J.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
[29] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
Judith Lorenz, Kuenzell
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
[30] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Matikas, A.
Lovrot, J.
Ramberg, A.
Eriksson, M.
Lindsten, T.
Lekberg, T.
Hedenfalk, I.
Loman, N.
Bergh, J.
Erlandsson, A.
Hatschek, T.
Foukakis, T.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →